Biogen To Acquire RayThera In $1 Billion Deal To Expand Immunology Pipeline

Biogen agreed to acquire privately held RayThera in a deal valued at up to $1 billion, including an upfront payment plus additional clinical and regulatory milestones. The acquisition expands Biogen's immunology pipeline with small-molecule therapies and signals continued M&A investment in biotech innovation. The announced size makes it material for Biogen and relevant to the broader healthcare M&A space.

Analysis

Biogen agreed to acquire privately held RayThera in a deal valued at up to $1 billion, including an upfront payment plus additional clinical and regulatory milestones. The acquisition expands Biogen's immunology pipeline with small-molecule therapies and signals continued M&A investment in biotech innovation. The announced size makes it material for Biogen and relevant to the broader healthcare M&A space.